Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
about
Hormone therapy for preventing cardiovascular disease in post-menopausal womenHormone therapy in postmenopausal women and risk of endometrial hyperplasiaHormone therapy for sexual function in perimenopausal and postmenopausal womenHormone therapy in postmenopausal women and risk of endometrial hyperplasiaEstrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.Postmenopausal syndromeClinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophyComparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal womenThe hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosisAdvances in the treatment of menopausal symptoms.Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model.Conjugated estrogens for the treatment of menopausal symptoms: a review of safety data.Advances in hormone replacement therapy: making the menopause manageableClinically meaningful efficacy of a non-estrogen agent: re-analysis of phase-2 data evaluating MF101.The 2012 hormone therapy position statement of: The North American Menopause Society.Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis.Acupuncture and auricular acupressure in relieving menopausal hot flashes of bilaterally ovariectomized chinese women: a randomized controlled trialPooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.Treatment of menopausal symptoms post-Women's Health Initiative: refinement of existing treatments and development of new therapies.Commentary: What's the deal with menopause management? Why the Women's Health Initiative raises more questions than it answers.Attitudes toward hormone replacement therapy in the new millennium: university physicians' and patients' perspectives.Overcoming resistance and barriers to the use of local estrogen therapy for the treatment of vaginal atrophyHormone therapy in the WHI era.Treating vasomotor symptoms of menopause: the nurse practitioner's perspective.Care of the menopausal patient: a nurse practitioner's view.New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk.Breast tenderness after initiation of conjugated equine estrogens and mammographic density change.Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007.Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trialsTreatment of vasomotor symptoms in the menopausal transition and postmenopausally: psychiatric comorbidity.Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fractureSafety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review.The tissue selective estrogen complex: a promising new menopausal therapyMenopausal hot flushes revisited.A new approach to menopausal therapy: the tissue selective estrogen complex.Menopause management: a cardiovascular risk-based approach.Menopausal hot flushes and night sweats: where are we now?Advances in menopausal therapy: the tissue-selective estrogen complex.Micro-dose transdermal estradiol for relief of hot flushes in postmenopausal Asian women: a randomized controlled trial.
P2860
Q24187326-9E6AEF5D-A3CA-40C4-8DC1-446AECF5DB3FQ24201543-F66BC7EE-3243-4883-ADCA-9857F3B97406Q24202201-14DB683E-CA75-4507-B26A-78CC007FDCD0Q24241713-263366B4-B7B1-4638-998C-584931A097A2Q24658109-5AF1A1E1-144D-41BE-B7BB-5D701D5DB7D7Q26795412-7ECE8C9F-959C-454D-AD8B-688D8F98CBA7Q28066699-EE929394-038F-4346-9008-F5B096413485Q28257427-42F02124-A0EF-4B47-8AC3-DC9B25DFBBD9Q28263058-8BB6CDE4-D7B3-4973-B0B5-58D7FEA95A08Q30448720-C1C23422-DB36-42F1-83A0-35703C3CE67CQ30456770-763031D6-317F-4100-A857-4419278DB7DEQ30659580-2FE79DDC-58E4-488A-AEC8-16E14B842B38Q33387664-1D6C542B-DD5F-438C-BFF8-FDB7298058A7Q34132246-63FC3919-ADDF-44DF-9060-2CC0C9F039AAQ34161400-15991D2E-3784-483B-B171-F5BC89393BD2Q34266113-375FCE65-E94C-46A1-A391-6DAFD13754F1Q34704488-92ECB04C-0325-41DC-B0B4-D2D07E181A90Q35108123-ECDA8887-9E08-4EF2-91D5-76A2B30A638DQ35919965-9436AEAF-5997-4B43-8F13-B6AFEADE2427Q36219667-0DC9B67F-FD79-4C21-950B-BFDC3AD0BAAFQ36257886-F4DB3117-CEBF-49C4-9B9B-B21B61AA056AQ36278168-2F7F15F1-FEE3-4B3B-8586-C8660AEE6358Q36326412-AFEEC447-4215-4C79-9610-8E63D13E79DEQ36459544-965AF2D6-95B1-4370-9A94-D104E7777B09Q36753044-9C4FB517-5A94-40ED-84FF-9AB485228BE8Q36892860-D7422AA7-E844-4D62-8A47-A7454CC4C1FDQ36896822-9D4BD6BB-8493-4013-8C57-8FB19A7FF8EBQ36937185-D9A09148-5EDC-4B15-920D-B3BAB54CA7B3Q36970351-4EF9B46A-DF25-4E21-8BD1-8F38E59A5597Q36971892-27DA5608-CED1-40F5-BFBF-2CCACFCEB97AQ37014593-2346FACF-CFA9-40F8-B0A2-64CC28631BB3Q37048294-9BEECB3A-AB33-4409-93D9-DE90DCEDD6A3Q37199888-AA7BFF8B-212C-4AA2-A0F9-6E922D602CB1Q37277298-3F67579D-5A9D-4AA7-9325-CCC2E7AA5134Q37342902-C4243228-67A9-430B-92B2-27B05FEEE6F6Q37352516-239F0177-3351-4057-8D97-7C352726BA56Q37650406-F2C3AE0A-BB13-4549-8320-32EF99A7939CQ37919098-EF3B3488-FB8E-498A-B924-895866EB4158Q38161857-F27E6493-4370-4B40-95A9-33B911A4C753Q39303005-97BE8682-A53E-4BFB-A2F7-D5C460A1DDD3
P2860
Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Relief of vasomotor symptoms a ...... d medroxyprogesterone acetate.
@ast
Relief of vasomotor symptoms a ...... d medroxyprogesterone acetate.
@en
type
label
Relief of vasomotor symptoms a ...... d medroxyprogesterone acetate.
@ast
Relief of vasomotor symptoms a ...... d medroxyprogesterone acetate.
@en
prefLabel
Relief of vasomotor symptoms a ...... d medroxyprogesterone acetate.
@ast
Relief of vasomotor symptoms a ...... d medroxyprogesterone acetate.
@en
P2093
P1476
Relief of vasomotor symptoms a ...... d medroxyprogesterone acetate.
@en
P2093
G Bachmann
J H Pickar
J V Pinkerton
P304
P356
10.1016/S0015-0282(01)01791-5
P407
P577
2001-06-01T00:00:00Z